Neurocrine Biosciences (NBIX) Competitors $135.43 +0.15 (+0.11%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$135.46 +0.03 (+0.02%) As of 08/22/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. BIIB, INCY, UTHR, BMRN, EXEL, MDGL, HALO, EXAS, IONS, and RGENShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Biogen Incyte United Therapeutics BioMarin Pharmaceutical Exelixis Madrigal Pharmaceuticals Halozyme Therapeutics Exact Sciences Ionis Pharmaceuticals Repligen Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends. Do analysts rate BIIB or NBIX? Biogen currently has a consensus price target of $185.74, indicating a potential upside of 33.33%. Neurocrine Biosciences has a consensus price target of $159.50, indicating a potential upside of 17.77%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is BIIB or NBIX more profitable? Biogen has a net margin of 15.31% compared to Neurocrine Biosciences' net margin of 13.88%. Biogen's return on equity of 13.85% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Neurocrine Biosciences 13.88%13.22%9.39% Which has more risk and volatility, BIIB or NBIX? Biogen has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Does the media favor BIIB or NBIX? In the previous week, Biogen had 25 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 39 mentions for Biogen and 14 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.48 beat Biogen's score of 1.18 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 27 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BIIB or NBIX? 87.9% of Biogen shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings & valuation, BIIB or NBIX? Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.11$1.63B$10.4613.32Neurocrine Biosciences$2.36B5.70$341.30M$3.3840.07 SummaryNeurocrine Biosciences beats Biogen on 9 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.43B$2.54B$5.83B$9.78BDividend YieldN/A1.67%4.40%4.05%P/E Ratio40.075.4322.8124.74Price / Sales5.70752.08473.17122.93Price / Cash40.07179.1038.0259.36Price / Book4.985.939.536.60Net Income$341.30M$31.83M$3.26B$265.65M7 Day Performance1.90%1.89%2.14%2.02%1 Month Performance1.32%1.33%2.81%-0.32%1 Year Performance-11.37%8.84%30.70%19.06% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8608 of 5 stars$135.43+0.1%$159.50+17.8%-11.2%$13.43B$2.36B40.071,800News CoveragePositive NewsBIIBBiogen4.8451 of 5 stars$128.00-2.0%$185.63+45.0%-31.5%$18.77B$9.68B12.247,605News CoveragePositive NewsINCYIncyte4.7195 of 5 stars$79.19+1.0%$81.20+2.5%+34.9%$15.46B$4.24B18.002,617Trending NewsAnalyst ForecastUTHRUnited Therapeutics4.9237 of 5 stars$300.43-0.4%$379.69+26.4%-10.0%$13.55B$2.88B11.731,305Positive NewsInsider TradeAnalyst RevisionBMRNBioMarin Pharmaceutical4.997 of 5 stars$56.80-0.9%$93.17+64.0%-34.9%$10.91B$2.85B16.853,040Positive NewsEXELExelixis4.9267 of 5 stars$37.41-0.8%$44.44+18.8%+49.8%$10.07B$2.17B17.991,147Trending NewsAnalyst RevisionMDGLMadrigal Pharmaceuticals3.5219 of 5 stars$349.50+1.1%$430.43+23.2%+66.8%$7.76B$180.13M-27.2090News CoverageAnalyst ForecastInsider TradeAnalyst RevisionHALOHalozyme Therapeutics4.7017 of 5 stars$62.92+0.0%$66.56+5.8%+16.5%$7.75B$1.02B14.40390News CoveragePositive NewsEXASExact Sciences4.9296 of 5 stars$40.91-0.2%$68.14+66.6%-19.6%$7.75B$2.76B-7.537,000IONSIonis Pharmaceuticals4.641 of 5 stars$40.84-1.9%$59.38+45.4%-10.2%$6.51B$944.05M-22.201,069Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionRGENRepligen4.8542 of 5 stars$111.88+0.4%$169.45+51.5%-15.7%$6.29B$673.96M-447.501,778News CoveragePositive News Related Companies and Tools Related Companies Biogen Competitors Incyte Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Exact Sciences Competitors Ionis Pharmaceuticals Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access